Association between survivin 31GC promoter polymorphism and cancer risk: A meta-analysis

European Journal of Human Genetics

Volumn 20, Issue 7, 2012, Pages 790-795

  Wang, Xiefeng ^a   Huang, Lili ^a   Xu, Yanjie ^a   Shi, Zhumei ^a   Wang, Yingyi ^a   Zhang, Junxia ^b   Wang, Xirui ^a   Cao, Lei ^a   Luo, Hui ^a   Chen, Jiawei ^a   Liu, Ning ^a   Yin, Yongmei ^a   You, Yongping ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

carcinoma; genetic polymorphism; meta analysis; Survivin; susceptibility

Indexed keywords

ARTICLE; CANCER RISK; DNA POLYMORPHISM; ETHNICITY; GENE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; SURVIVIN GENE; ALLELE; ASIAN; CASE CONTROL STUDY; CONFIDENCE INTERVAL; ETHNIC GROUP; ETHNOLOGY; GENETIC HETEROGENEITY; GENETIC POLYMORPHISM; GENETICS; NEOPLASM; PROMOTER REGION; RISK; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN;

ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ETHNIC GROUPS; GENE FREQUENCY; GENETIC HETEROGENEITY; GENOTYPE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; NEOPLASMS; ODDS RATIO; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84863725816     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2011.276     Document Type: Article

References (59)

1. Pharoah PD, Dunning AM, Ponder BA, Easton DF: Association studies for finding cancer-susceptibility genetic variants. Nat Rev 2004; 4: 850-860. (Pubitemid 39472952)
2. Mondello C, Scovassi AI: Apoptosis: a way to maintain healthy individuals. Subcell Biochem 2010; 50: 307-323.
3. Raff M: Cell suicide for beginners. Nature 1998; 396: 119-122. (Pubitemid 28523602)
4. Delhalle S, Duvoix A, Schnekenburger M, Morceau F, Dicato M, Diederich M: An introduction to the molecular mechanisms of apoptosis. Ann NY Acad Sci 2003; 1010: 1-8. (Pubitemid 38264943)
5. Degterev A, Boyce M, Yuan J: A decade of caspases. Oncogene 2003; 22: 8543-8567. (Pubitemid 38028527)
6. Hajra KM, Liu JR: Apoptosome dysfunction in human cancer. Apoptosis 2004; 9: 691-704. (Pubitemid 40941198)
7. Ambrosini G, Adida C, Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921. (Pubitemid 27353455)
8. Li F, Ambrosini G, Chu EY et al: Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584. (Pubitemid 28563719)
9. Altieri DC: The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 2001; 7: 542-547. (Pubitemid 33127139)
10. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
11. Ambrosini G, Adida C, Sirugo G, Altieri DC: Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting. J Biol Chem 1998; 273: 11177-11182. (Pubitemid 28204967)
12. Xu Y, Fang F, Ludewig G, Jones G, Jones D: A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 2004; 23: 527-537. (Pubitemid 39244331)
13. Jang JS, Kim KM, Kang KH et al: Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 2008; 60: 31-39. (Pubitemid 351434465)
14. Borbely AA, Murvai M, Szarka K et al: Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 2007; 60: 303-306. (Pubitemid 46447748)
15. Kawata N, Tsuchiya N, Horikawa Y et al: Two survivin polymorphisms are cooperatively associated with bladder cancer susceptibility. Int J Cancer 2010; 129: 1872-1880.
16. Borges BD, Burbano RR, Harada ML: Survivin 31C/G polymorphism and gastric cancer risk in a Brazilian population. Clin Exp Med 2011; 11: 189-193.
17. Theodoropoulos GE, Michalopoulos NV, Panoussopoulos SG, Taka S, Gazouli M: Effects of caspase-9 and survivin gene polymorphisms in pancreatic cancer risk and tumor characteristics. Pancreas 2010; 39: 976-980.
18. Wang YH, Chiou HY, Lin CT et al: Association between survivin gene promoter 31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 2009; 73: 670-674.
19. Gazouli M, Tzanakis N, Rallis G et al: Survivin 31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 2009; 24: 145-150.
20. Yang X, Xiong G, Chen X et al: Polymorphisms of survivin promoter are associated with risk of esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2009; 135: 1341-1349.
21. Upadhyay R, Khurana R, Kumar S, Ghoshal UC, Mittal B: Role of survivin gene promoter polymorphism (31G4C) in susceptibility and survival of esophageal cancer in Northern India. Ann Surg Oncol 2011; 18: 880-887.
22. Cheng ZJ, Hu LH, Huang SJ: [Correlation of 31G/C polymorphisms of survivin promoter to tumorigenesis of gastric carcinoma]. Ai Zheng 2008; 27: 258-263.
23. Yang L, Zhu H, Zhou B et al: The association between the survivin C-31G polymorphism and gastric cancer risk in a Chinese population. Dig Dis Sci 2009; 54: 1021-1028.
24. Bayram S, Akkiz H, Bekar A, Akgollu E: The association between the Survivin 31G/C promoter polymorphism and hepatocellular carcinoma risk in a Turkish population. Cancer Epidemiol 2011; 35: 555-559.
25. Ma F, Zhang H, Zhai Y et al: Functional polymorphism 31C/G in the promoter of BIRC5 gene and risk of nasopharyngeal carcinoma among Chinese. PLoS One 2011; 6: e16748.
26. Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
27. DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188. (Pubitemid 17189972)
28. Wang YH, Chen DJ, Yi TN, Liu XH: The relationship among human papilloma virus infection, survivin, and p53 gene in lung squamous carcinoma tissue. Saudi Med J 2010; 31: 1331-1336.
29. Wang H, Holloway MP, Ma L et al: Acetylation directs survivin nuclear localization to repress STAT3 oncogenic activity. J Biol Chem 2010; 285: 36129-36137.
30. Krepela E, Dankova P, Moravcikova E et al: Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma. Int J Oncol 2009; 35: 1449-1462.
31. Farnebo L, Jerhammar F, Vainikka L, Grenman R, Norberg-Spaak L, Roberg K: Number of negative points: a novel method for predicting radiosensitivity in head and neck tumor cell lines. Oncol Rep 2008; 20: 453-461.
32. Wagner M, Schmelz K, Dorken B, Tamm I: Epigenetic and genetic analysis of the survivin promoter in acute myeloid leukemia. Leuk Res 2008; 32: 1054-1060.
33. Boidot R, Vegran F, Jacob D et al: The expression of BIRC5 is correlated with loss of specific chromosomal regions in breast carcinomas. Genes Chromosomes Cancer 2008; 47: 299-308. (Pubitemid 351323759)
34. Vegran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S: Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007; 26: 290-297. (Pubitemid 46095740)
35. Floyd HS, Jennings-Gee JE, Kock ND, Miller MS: Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. Mol Carcinog 2006; 45: 506-517.
36. Nakano J, Huang CL, Liu D, Ueno M, Sumitomo S, Yokomise H: Survivin gene expression is negatively regulated by the p53 tumor suppressor gene in non-small cell lung cancer. Int J Oncol 2005; 27: 1215-1221.
37. Teodoridis JM, Hall J, Marsh S et al: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 2005; 65: 8961-8967. (Pubitemid 41377387)
38. Kimura M, Okano Y: [Aurora kinases and cancer]. Gan To Kagaku Ryoho 2005; 32: 1-5.
39. Saitoh Y, Yaginuma Y, Ishikawa M: Analysis of Bcl-2, Bax and Survivin genes in uterine cancer. Int J Oncol 1999; 15: 137-141.
40. Boidot R, Vegran F, Jacob D et al: The transcription factor GATA-1 is overexpressed in breast carcinomas and contributes to survivin upregulation via a promoter polymorphism. Oncogene 2010; 29: 2577-2584.
41. Farnebo L, Jedlinski A, Ansell A et al: Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines. Int J Mol Med 2009; 24: 549-556.
42. Loof J, Pfeifer D, Adell G, Sun XF: Significance of an exon 2 G4C14-to-A4T14 polymorphism in the p73 gene on survival in rectal cancer patients with or without preoperative radiotherapy. Radiother Oncol 2009; 92: 215-220.
43. Yang X, Xiong G, Chen X et al: Survivin expression in esophageal cancer: correlation with p53 mutations and promoter polymorphism. Dis Esophagus 2009; 22: 223-230.
44. Han CH, Wei Q, Lu KK, Liu Z, Mills GB, Wang LE: Polymorphisms in the survivin promoter are associated with age of onset of ovarian cancer. Int J Clin Exp Med 2009; 2: 289-299.
45. Duffy MJ, O'Donovan N, Brennan DJ, Gallagher WM, Ryan BM: Survivin: a promising tumor biomarker. Cancer Lett 2007; 249: 49-60. (Pubitemid 46442669)
46. Melet A, Song K, Bucur O, Jagani Z, Grassian AR, Khosravi-Far R: Apoptotic pathways in tumor progression and therapy. Adv Exp Med Biol 2008; 615: 47-79.
47. Fukuda S, Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5: 1087-1098. (Pubitemid 43881300)
48. Altieri DC: Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3: 46-54. (Pubitemid 37328886)
49. Reed JC: The Survivin saga goes in vivo. J Clin Invest 2001; 108: 965-969. (Pubitemid 32946070)
50. Tamm I, Wang Y, Sausville E et al: IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320. (Pubitemid 28551107)
51. Shin S, Sung BJ, Cho YS et al: An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and-7. Biochemistry 2001; 40: 1117-1123. (Pubitemid 32108606)
52. Sun C, Nettesheim D, Liu Z, Olejniczak ET: Solution structure of human survivin and its binding interface with Smac/Diablo. Biochemistry 2005; 44: 11-17. (Pubitemid 40095702)
53. Liu T, Brouha B, Grossman D: Rapid induction of mitochondrial events and caspase-independent apoptosis in Survivin-targeted melanoma cells. Oncogene 2004; 23: 39-48. (Pubitemid 38142238)
54. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC: Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003; 362: 205-209. (Pubitemid 36859937)
55. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L: Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006; 281: 25903-25914. (Pubitemid 44401796)
56. Li F, Altieri DC: The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. Cancer Res 1999; 59: 3143-3151. (Pubitemid 29316014)
57. Otaki M, Hatano M, Kobayashi K, Ogasawara T, Kuriyama T, Tokuhisa T: Cell cycledependent regulation of TIAP/m-survivin expression. Biochim Biophys Acta 2000; 1493: 188-194.
58. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K: A comprehensive review of genetic association studies. Genet Med 2002; 4: 45-61. (Pubitemid 44698579)
59. Wang Y, Yang H, Li H et al: Association between X-ray repair cross complementing group 1 codon 399 and 194 polymorphisms and lung cancer risk: a meta-analysis. Cancer Lett 2009; 285: 134-140.